RHI
50
2
FIS
48
5
CRM
67
2
PEG
57
2
IVZ
48
3
PDCO
77
2
KLAC
59
3
WU
16
4
EXPE
88
2
HES
53
4
D
35
2
AVY
47
3
UNP
40
2
HPQ
57
2
CINF
38
3
CNP
54
4
MPC
31
3
PX
58
5
OKE
67
5
COF
52
5
RHI
50
2
FIS
48
5
CRM
67
2
PEG
57
2
IVZ
48
3
PDCO
77
2
KLAC
59
3
WU
16
4
EXPE
88
2
HES
53
4
D
35
2
AVY
47
3
UNP
40
2
HPQ
57
2
CINF
38
3
CNP
54
4
MPC
31
3
PX
58
5
OKE
67
5
COF
52
5
Financhill
Back

Protalix BioTherapeutics 10K Form

Buy
71

PLX
Protalix BioTherapeutics

Last Price:
$1.80
Seasonality Move:
19.62%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive PLX News And Ratings

See the #1 stock for the next 7 days that we like better than PLX

PLX Financial Statistics

Sales & Book Value

Annual Sales: $65.5M
Cash Flow: $4M
Price / Cash Flow: 19.49
Annual Sales: $0.44
Price / Book: 4.04

Profitability

EPS (TTM): -0.16000
Net Income (TTM): $-9.6M
Gross Margin: $42.5M
Return on Equity: -29.54%
Return on Assets: -11.58%

Protalix BioTherapeutics Earnings Forecast

Key Protalix BioTherapeutics Financial Ratios

  • The Gross Profit Margin over the past 26 years for PLX is 64.91%.
  • The Selling, General & Administrative Expenses for PLX have been equal to 22.84% of Gross Profit Margin.
  • The Research & Development expenses have been 26.10% of Revenue.
  • The Interest Expense is 38.26% of Operating Income.
  • The Net Earning history of PLX is 12.69% of Total Revenues.
  • Per Share Earnings over the last 28 years have been positive in 13 years.

Protalix BioTherapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NYAM
Industry: Biotechnology
Sector: Health Care
Current Symbol: PLX
CUSIP: 74365A
Website: protalix.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 1.98
Quick Ratio: 1.22

Price-to-Earnings

Trailing P/E Ratio: 19.78
Forward P/E Ratio: 0

PLX Technical Analysis vs Fundamental Analysis

Buy
71
Protalix BioTherapeutics (PLX) is a Buy

Is Protalix BioTherapeutics a Buy or a Sell?